首页 > 最新文献

Journal of Infectious Diseases最新文献

英文 中文
The Fading of the Mpox Outbreak Among Men Who Have Sex With Men: A Mathematical Modelling Study. 男男性行为者中痘病毒爆发的消退:数学模型研究
IF 5 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-07-25 DOI: 10.1093/infdis/jiad414
Maria Xiridou, Fuminari Miura, Philippe Adam, Eline Op de Coul, John de Wit, Jacco Wallinga

Background: In the Netherlands, the number of mpox cases started declining before mpox vaccination was initiated. Most cases were men who have sex with men (MSM). We investigated whether the decline in mpox could be attributed to infection-induced immunity or behavioral adaptations.

Methods: We developed a transmission model and accounted for possible behavioral adaptations: fewer casual partners and shorter time until MSM with mpox refrain from sexual contacts.

Results: Without behavioral adaptations, the peak in modelled cases matched observations, but the decline was less steep than observed. With behavioral adaptations in the model, we found a decline of 16%-18% in numbers of casual partners in June and 13%-22% in July 2022. Model results showed a halving of the time before refraining from sex. When mpox vaccination started, 57% of MSM with very high sexual activity in the model had been infected. Model scenarios revealed that the outbreak could have waned by November 2022 even without vaccination.

Conclusions: The limited duration of the mpox outbreak in the Netherlands can be ascribed primarily to infection-induced immunity among MSM with high sexual activity levels. The decline was accelerated by behavioral adaptations. Immunity among those most sexually active is essential to impede mpox resurgence.

背景:在荷兰,在开始接种麻疹疫苗之前,麻疹病例的数量就已经开始下降。大多数病例为男男性行为者(MSM)。我们研究了水痘病例的减少是否可归因于感染引起的免疫或行为适应:方法:我们建立了一个传播模型,并考虑了可能的行为适应性:较少的临时性伴侣和较短的时间,直到患有痘病的 MSM 避免性接触:结果:在没有行为适应的情况下,模型中病例的峰值与观察结果一致,但下降的幅度小于观察结果。在对模型进行行为调整后,我们发现 2022 年 6 月的临时性伴侣数量下降了 16%-18%,7 月下降了 13%-22%。模型结果显示,不发生性行为的时间缩短了一半。当 mpox 疫苗接种开始时,模型中 57% 性活动频繁的 MSM 已受到感染。模型情景显示,即使不接种疫苗,疫情也可能在 2022 年 11 月之前消退:结论:荷兰的麻疹疫情持续时间有限,这主要归因于性活动频繁的男男性行为者因感染而产生的免疫力。行为适应加速了免疫力的下降。性生活最活跃人群的免疫力对于阻止麻疹痘的复发至关重要。
{"title":"The Fading of the Mpox Outbreak Among Men Who Have Sex With Men: A Mathematical Modelling Study.","authors":"Maria Xiridou, Fuminari Miura, Philippe Adam, Eline Op de Coul, John de Wit, Jacco Wallinga","doi":"10.1093/infdis/jiad414","DOIUrl":"10.1093/infdis/jiad414","url":null,"abstract":"<p><strong>Background: </strong>In the Netherlands, the number of mpox cases started declining before mpox vaccination was initiated. Most cases were men who have sex with men (MSM). We investigated whether the decline in mpox could be attributed to infection-induced immunity or behavioral adaptations.</p><p><strong>Methods: </strong>We developed a transmission model and accounted for possible behavioral adaptations: fewer casual partners and shorter time until MSM with mpox refrain from sexual contacts.</p><p><strong>Results: </strong>Without behavioral adaptations, the peak in modelled cases matched observations, but the decline was less steep than observed. With behavioral adaptations in the model, we found a decline of 16%-18% in numbers of casual partners in June and 13%-22% in July 2022. Model results showed a halving of the time before refraining from sex. When mpox vaccination started, 57% of MSM with very high sexual activity in the model had been infected. Model scenarios revealed that the outbreak could have waned by November 2022 even without vaccination.</p><p><strong>Conclusions: </strong>The limited duration of the mpox outbreak in the Netherlands can be ascribed primarily to infection-induced immunity among MSM with high sexual activity levels. The decline was accelerated by behavioral adaptations. Immunity among those most sexually active is essential to impede mpox resurgence.</p>","PeriodicalId":50179,"journal":{"name":"Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11272055/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hemagglutination Inhibition Antibody Titers as Mediators of Influenza Vaccine Efficacy Against Symptomatic Influenza A(H1N1), A(H3N2), and B/Victoria Virus Infections. 血凝抑制抗体滴度作为流感疫苗对无症状甲型 H1N1、甲型 H3N2 和乙型 Victoria 病毒感染疗效的媒介。
IF 5 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-07-25 DOI: 10.1093/infdis/jiae122
Wey Wen Lim, Shuo Feng, Sook-San Wong, Sheena G Sullivan, Benjamin J Cowling

Background: The hemagglutination inhibition antibody (HAI) titer contributes only a part of vaccine-induced protection against influenza virus infections. Using causal mediation analysis, we quantified the proportion of vaccine efficacy mediated by postvaccination HAI titers.

Methods: We conducted causal mediation analyses using data from a randomized, active-comparator controlled, phase III, trial of an inactivated, split-virion seasonal quadrivalent influenza vaccine in children conducted from October 2010 to December 2011 in 8 countries. Vaccine efficacy was estimated using a weighted Cox proportional hazards model. Estimates were decomposed into the direct and indirect effects mediated by postvaccination HAI titers.

Results: The proportions of vaccine efficacy mediated by postvaccination HAI titers were estimated to be 22% (95% confidence interval, 18%--47%) for influenza A(H1N1), 20% (16%-39%) for influenza A(H3N2), and 37% (26%-85%) for influenza B/Victoria.

Conclusions: HAI titers partially mediate influenza vaccine efficacy against influenza A(H1N1), A(H3N2), and B/Victoria. Our estimates were lower than in previous studies, possibly reflecting expected heterogeneity in antigenic similarity between vaccine and circulating viruses across seasons.

背景:血凝抑制抗体(HAI)滴度只占疫苗诱导的流感病毒感染保护作用的一部分。通过因果中介分析,我们量化了疫苗接种后 HAI 滴度在疫苗疗效中所占的比例:我们利用 2010 年 10 月至 2011 年 12 月在 8 个国家进行的儿童四价季节性流感灭活疫苗分病毒 III 期随机对照试验的数据进行了因果中介分析。疫苗疗效采用加权考克斯比例危险模型进行估算。估算结果分解为接种后 HAI 滴度介导的直接和间接影响:甲型 H1N1 流感疫苗接种后 HAI 滴度介导的疫苗效力比例估计为 22%(95% 置信区间,18%-47%),甲型 H3N2 流感为 20%(16%-39%),乙型/维多利亚流感为 37%(26%-85%):结论:HAI 滴度部分介导了流感疫苗对甲型 H1N1、甲型 H3N2 和乙型 Victoria 流感的效力。我们的估计值低于以往的研究,这可能反映了不同季节疫苗和流行病毒之间抗原相似性的预期异质性。
{"title":"Hemagglutination Inhibition Antibody Titers as Mediators of Influenza Vaccine Efficacy Against Symptomatic Influenza A(H1N1), A(H3N2), and B/Victoria Virus Infections.","authors":"Wey Wen Lim, Shuo Feng, Sook-San Wong, Sheena G Sullivan, Benjamin J Cowling","doi":"10.1093/infdis/jiae122","DOIUrl":"10.1093/infdis/jiae122","url":null,"abstract":"<p><strong>Background: </strong>The hemagglutination inhibition antibody (HAI) titer contributes only a part of vaccine-induced protection against influenza virus infections. Using causal mediation analysis, we quantified the proportion of vaccine efficacy mediated by postvaccination HAI titers.</p><p><strong>Methods: </strong>We conducted causal mediation analyses using data from a randomized, active-comparator controlled, phase III, trial of an inactivated, split-virion seasonal quadrivalent influenza vaccine in children conducted from October 2010 to December 2011 in 8 countries. Vaccine efficacy was estimated using a weighted Cox proportional hazards model. Estimates were decomposed into the direct and indirect effects mediated by postvaccination HAI titers.</p><p><strong>Results: </strong>The proportions of vaccine efficacy mediated by postvaccination HAI titers were estimated to be 22% (95% confidence interval, 18%--47%) for influenza A(H1N1), 20% (16%-39%) for influenza A(H3N2), and 37% (26%-85%) for influenza B/Victoria.</p><p><strong>Conclusions: </strong>HAI titers partially mediate influenza vaccine efficacy against influenza A(H1N1), A(H3N2), and B/Victoria. Our estimates were lower than in previous studies, possibly reflecting expected heterogeneity in antigenic similarity between vaccine and circulating viruses across seasons.</p>","PeriodicalId":50179,"journal":{"name":"Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11272062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New Publishing Strategy at JID. JID 的新出版战略。
IF 5 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-07-25 DOI: 10.1093/infdis/jiae326
Cynthia L Sears
{"title":"New Publishing Strategy at JID.","authors":"Cynthia L Sears","doi":"10.1093/infdis/jiae326","DOIUrl":"10.1093/infdis/jiae326","url":null,"abstract":"","PeriodicalId":50179,"journal":{"name":"Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spliced-Leader RNA as a Dynamic Marker for Monitoring Viable Leishmania Parasites During and After Treatment. 剪接前导 RNA 作为动态标记物,用于监测治疗期间和治疗后的利什曼病寄生虫存活情况
IF 5 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-07-25 DOI: 10.1093/infdis/jiae219
Rik Hendrickx, Roma Melkamu, Dagimawie Tadesse, Tedla Teferi, Pim-Bart Feijens, Margot Vleminckx, Saskia van Henten, Fabiana Alves, Tamiru Shibru, Johan van Griensven, Guy Caljon, Myrthe Pareyn

Accurate detection of viable Leishmania parasites is critical for evaluating visceral leishmaniasis (VL) treatment response at an early timepoint. We compared the decay of kinetoplast DNA (kDNA) and spliced-leader RNA (SL-RNA) in vitro, in vivo, and in a VL patient cohort. An optimized combination of blood preservation and nucleic acid extraction improved efficiency for both targets. SL-RNA degraded more rapidly during treatment than kDNA, and correlated better with microscopic examination. SL-RNA quantitative polymerase chain reaction emerges as a superior method for dynamic monitoring of viable Leishmania parasites. It enables individualized treatment monitoring for improved prognoses and has potential as an early surrogate endpoint in clinical trials.

准确检测存活的利什曼病寄生虫对于早期评估内脏利什曼病(VL)治疗反应至关重要。我们比较了体外、体内和 VL 患者队列中的动粒 DNA(kDNA)和剪接头 RNA(SL-RNA)的衰变情况。血液保存和核酸提取的优化组合提高了两个目标的效率。与 kDNA 相比,SL-RNA 在治疗过程中降解得更快,而且与显微镜检查的相关性更好。SL-RNA定量聚合酶链反应是动态监测存活利什曼寄生虫的优越方法。它能进行个体化治疗监测以改善预后,并有可能成为临床试验中的早期替代终点。
{"title":"Spliced-Leader RNA as a Dynamic Marker for Monitoring Viable Leishmania Parasites During and After Treatment.","authors":"Rik Hendrickx, Roma Melkamu, Dagimawie Tadesse, Tedla Teferi, Pim-Bart Feijens, Margot Vleminckx, Saskia van Henten, Fabiana Alves, Tamiru Shibru, Johan van Griensven, Guy Caljon, Myrthe Pareyn","doi":"10.1093/infdis/jiae219","DOIUrl":"10.1093/infdis/jiae219","url":null,"abstract":"<p><p>Accurate detection of viable Leishmania parasites is critical for evaluating visceral leishmaniasis (VL) treatment response at an early timepoint. We compared the decay of kinetoplast DNA (kDNA) and spliced-leader RNA (SL-RNA) in vitro, in vivo, and in a VL patient cohort. An optimized combination of blood preservation and nucleic acid extraction improved efficiency for both targets. SL-RNA degraded more rapidly during treatment than kDNA, and correlated better with microscopic examination. SL-RNA quantitative polymerase chain reaction emerges as a superior method for dynamic monitoring of viable Leishmania parasites. It enables individualized treatment monitoring for improved prognoses and has potential as an early surrogate endpoint in clinical trials.</p>","PeriodicalId":50179,"journal":{"name":"Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Levels of Angiopoietin 2 Are Predictive for Mortality in Patients Infected With Yellow Fever Virus. 血管生成素 2 的水平可预测黄热病病毒感染者的死亡率
IF 5 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-07-25 DOI: 10.1093/infdis/jiad389
Cornelia A M van de Weg, Mateus V Thomazella, Mariana P Marmorato, Carolina A Correia, Juliana Z C Dias, Alvino Maestri, Luiz G F A B E Zanella, Natalia B Cerqueira, Alvina C Félix, Carlos H V Moreira, Renata Buccheri, Priscilla R Costa, Esper G Kallás

In 2018 there was a large yellow fever outbreak in São Paulo, Brazil, with a high fatality rate. Yellow fever virus can cause, among other symptoms, hemorrhage and disseminated intravascular coagulation, indicating a role for endothelial cells in disease pathogenesis. Here, we conducted a case-control study and measured markers related to endothelial damage in plasma and its association with mortality. We found that angiopoietin 2 is strongly associated with a fatal outcome and could serve as a predictive marker for mortality. This could be used to monitor severe cases and provide care to improve disease outcome.

2018 年,巴西圣保罗爆发了大规模黄热病疫情,死亡率很高。黄热病病毒可引起出血和弥散性血管内凝血等症状,表明内皮细胞在疾病发病机制中发挥作用。在此,我们进行了一项病例对照研究,测量了血浆中与内皮损伤有关的标记物及其与死亡率的关系。我们发现血管生成素 2 与死亡结果密切相关,可作为预测死亡率的标志物。这可用于监测严重病例,并提供护理以改善疾病预后。
{"title":"Levels of Angiopoietin 2 Are Predictive for Mortality in Patients Infected With Yellow Fever Virus.","authors":"Cornelia A M van de Weg, Mateus V Thomazella, Mariana P Marmorato, Carolina A Correia, Juliana Z C Dias, Alvino Maestri, Luiz G F A B E Zanella, Natalia B Cerqueira, Alvina C Félix, Carlos H V Moreira, Renata Buccheri, Priscilla R Costa, Esper G Kallás","doi":"10.1093/infdis/jiad389","DOIUrl":"10.1093/infdis/jiad389","url":null,"abstract":"<p><p>In 2018 there was a large yellow fever outbreak in São Paulo, Brazil, with a high fatality rate. Yellow fever virus can cause, among other symptoms, hemorrhage and disseminated intravascular coagulation, indicating a role for endothelial cells in disease pathogenesis. Here, we conducted a case-control study and measured markers related to endothelial damage in plasma and its association with mortality. We found that angiopoietin 2 is strongly associated with a fatal outcome and could serve as a predictive marker for mortality. This could be used to monitor severe cases and provide care to improve disease outcome.</p>","PeriodicalId":50179,"journal":{"name":"Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11272082/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Minimal Impact on the Resistome of Children in Botswana After Azithromycin Treatment for Acute Severe Diarrheal Disease. 阿奇霉素治疗急性严重腹泻病后对博茨瓦纳儿童抗药性的影响极小。
IF 5 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-07-25 DOI: 10.1093/infdis/jiae049
Allison K Guitor, Anna Katyukhina, Margaret Mokomane, Kwana Lechiile, David M Goldfarb, Gerard D Wright, Andrew G McArthur, Jeffrey M Pernica

Background: Macrolide antibiotics, including azithromycin, can reduce under 5 years of age mortality rates and treat various infections in children in sub-Saharan Africa. These exposures, however, can select for antibiotic-resistant bacteria in the gut microbiota.

Methods: Our previous randomized controlled trial (RCT) of a rapid-test-and-treat strategy for severe acute diarrheal disease in children in Botswana included an intervention (3-day azithromycin dose) group and a control group that received supportive treatment. In this prospective matched cohort study using stools collected at baseline and 60 days after treatment from RCT participants, the collection of antibiotic resistance genes or resistome was compared between groups.

Results: Certain macrolide resistance genes increased in prevalence by 13%-55% at 60 days, without differences in gene presence between the intervention and control groups. These genes were linked to tetracycline resistance genes and mobile genetic elements.

Conclusions: Azithromycin treatment for bacterial diarrhea for young children in Botswana resulted in similar effects on the gut resistome as the supportive treatment and did not provide additional selective pressure for macrolide resistance gene maintenance. The gut microbiota of these children contains diverse macrolide resistance genes that may be transferred within the gut upon repeated exposures to azithromycin or coselected by other antibiotics.

Clinical trials registration: NCT02803827.

背景:包括阿奇霉素在内的大环内酯类抗生素可以降低撒哈拉以南非洲地区 5 岁以下儿童的死亡率并治疗各种感染。然而,这些抗生素会在肠道微生物群中选择出抗生素耐药菌:我们之前在博茨瓦纳开展了一项针对儿童严重急性腹泻病的快速检测和治疗策略随机对照试验(RCT),其中包括一个干预组(3 天阿奇霉素剂量)和一个接受支持性治疗的对照组。在这项前瞻性配对队列研究中,研究人员利用在基线和治疗后 60 天收集的 RCT 参与者粪便,比较了各组间抗生素耐药基因或耐药组的收集情况:结果:某些大环内酯类抗生素耐药基因的流行率在 60 天后增加了 13%-55%,但干预组和对照组之间的基因存在率并无差异。这些基因与四环素耐药基因和移动遗传因子有关:结论:阿奇霉素治疗博茨瓦纳幼儿细菌性腹泻对肠道耐药基因组的影响与支持性治疗相似,并没有为大环内酯类耐药基因的维持提供额外的选择压力。这些儿童的肠道微生物群含有多种大环内酯类药物耐药基因,这些基因可能会在反复接触阿奇霉素后在肠道内转移,或被其他抗生素共同选择:临床试验注册:NCT02803827。
{"title":"Minimal Impact on the Resistome of Children in Botswana After Azithromycin Treatment for Acute Severe Diarrheal Disease.","authors":"Allison K Guitor, Anna Katyukhina, Margaret Mokomane, Kwana Lechiile, David M Goldfarb, Gerard D Wright, Andrew G McArthur, Jeffrey M Pernica","doi":"10.1093/infdis/jiae049","DOIUrl":"10.1093/infdis/jiae049","url":null,"abstract":"<p><strong>Background: </strong>Macrolide antibiotics, including azithromycin, can reduce under 5 years of age mortality rates and treat various infections in children in sub-Saharan Africa. These exposures, however, can select for antibiotic-resistant bacteria in the gut microbiota.</p><p><strong>Methods: </strong>Our previous randomized controlled trial (RCT) of a rapid-test-and-treat strategy for severe acute diarrheal disease in children in Botswana included an intervention (3-day azithromycin dose) group and a control group that received supportive treatment. In this prospective matched cohort study using stools collected at baseline and 60 days after treatment from RCT participants, the collection of antibiotic resistance genes or resistome was compared between groups.</p><p><strong>Results: </strong>Certain macrolide resistance genes increased in prevalence by 13%-55% at 60 days, without differences in gene presence between the intervention and control groups. These genes were linked to tetracycline resistance genes and mobile genetic elements.</p><p><strong>Conclusions: </strong>Azithromycin treatment for bacterial diarrhea for young children in Botswana resulted in similar effects on the gut resistome as the supportive treatment and did not provide additional selective pressure for macrolide resistance gene maintenance. The gut microbiota of these children contains diverse macrolide resistance genes that may be transferred within the gut upon repeated exposures to azithromycin or coselected by other antibiotics.</p><p><strong>Clinical trials registration: </strong>NCT02803827.</p>","PeriodicalId":50179,"journal":{"name":"Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11272098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to Dow and Smith. 答复 Dow 和 Smith。
IF 5 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-07-25 DOI: 10.1093/infdis/jiae194
Choukri Ben Mamoun, Gary P Wormser
{"title":"Reply to Dow and Smith.","authors":"Choukri Ben Mamoun, Gary P Wormser","doi":"10.1093/infdis/jiae194","DOIUrl":"10.1093/infdis/jiae194","url":null,"abstract":"","PeriodicalId":50179,"journal":{"name":"Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Signals From Inflamed Perivascular Adipose Tissue Contribute to Small-Vessel Dysfunction in Women With Human Immunodeficiency Virus. 发炎的血管周围脂肪组织发出的信号导致女性人类免疫缺陷病毒感染者的小血管功能障碍
IF 5 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-07-25 DOI: 10.1093/infdis/jiae094
Christopher S Wilcox, Carly Herbert, Cheng Wang, Yuchi Ma, Philena Sun, Tian Li, Jennifer Verbesey, Princy Kumar, Seble Kassaye, William J Welch, Michael J Choi, Negiin Pourafshar, Dan Wang

Background: People with the human immunodeficiency virus (PWH) have microvascular disease. Because perivascular adipose tissue (PVAT) regulates microvascular function and adipose tissue is inflamed in PWH, we tested the hypothesis that PWH have inflamed PVAT that impairs the function of their small vessels.

Methods: Subcutaneous small arteries were dissected with or without PVAT from a gluteal skin biopsy from 11 women with treated HIV (WWH) aged < 50 years and 10 matched women without HIV, and studied on isometric myographs. Nitric oxide (NO) and reactive oxygen species (ROS) were measured by fluorescence microscopy. Adipokines and markers of inflammation and ROS were assayed in PVAT.

Results: PVAT surrounding the small arteries in control women significantly (P < .05) enhanced acetylcholine-induced endothelium-dependent relaxation and NO, and reduced contractions to thromboxane and endothelin-1. However, these effects of PVAT were reduced significantly (P < .05) in WWH whose PVAT released less adiponectin but more markers of ROS and inflammation. Moderation of contractions by PVAT were correlated positively with adipose adiponectin.

Conclusions: PVAT from WWH has oxidative stress, inflammation, and reduced release of adiponectin, which may contribute to enhanced contractions and therefore could promote small-artery dysfunction.

背景:人类免疫缺陷病毒感染者(PWH)患有微血管疾病。由于血管周围脂肪组织(PVAT)可调节微血管功能,而 PWH 患者的脂肪组织会发炎,因此我们对 PWH 患者的 PVAT 发炎会损害其小血管功能的假设进行了测试:方法: 我们从 11 名年龄小于 50 岁、接受过艾滋病治疗的女性(WWH)和 10 名匹配的未感染艾滋病的女性的臀部皮肤活检组织中解剖出有或没有 PVAT 的皮下小动脉,并在等长肌电图上对其进行研究。通过荧光显微镜测量了一氧化氮(NO)和活性氧(ROS)。脂肪因子和炎症及 ROS 标记物在 PVAT 中进行了检测:结果:对照组女性小动脉周围的 PVAT 能显著(P < .05)增强乙酰胆碱诱导的内皮依赖性松弛和 NO,并能减少血栓素和内皮素-1 的收缩。然而,PVAT 的这些作用在 WWH 中明显降低(P < .05),因为 WWH 的 PVAT 释放的脂肪连通素较少,但释放的 ROS 和炎症标记物较多。PVAT对收缩的调节作用与脂肪的脂肪连素呈正相关:结论:WWH 患者的 PVAT 存在氧化应激、炎症和脂肪连蛋白释放减少的问题,这可能会导致收缩增强,从而促进小动脉功能障碍。
{"title":"Signals From Inflamed Perivascular Adipose Tissue Contribute to Small-Vessel Dysfunction in Women With Human Immunodeficiency Virus.","authors":"Christopher S Wilcox, Carly Herbert, Cheng Wang, Yuchi Ma, Philena Sun, Tian Li, Jennifer Verbesey, Princy Kumar, Seble Kassaye, William J Welch, Michael J Choi, Negiin Pourafshar, Dan Wang","doi":"10.1093/infdis/jiae094","DOIUrl":"10.1093/infdis/jiae094","url":null,"abstract":"<p><strong>Background: </strong>People with the human immunodeficiency virus (PWH) have microvascular disease. Because perivascular adipose tissue (PVAT) regulates microvascular function and adipose tissue is inflamed in PWH, we tested the hypothesis that PWH have inflamed PVAT that impairs the function of their small vessels.</p><p><strong>Methods: </strong>Subcutaneous small arteries were dissected with or without PVAT from a gluteal skin biopsy from 11 women with treated HIV (WWH) aged < 50 years and 10 matched women without HIV, and studied on isometric myographs. Nitric oxide (NO) and reactive oxygen species (ROS) were measured by fluorescence microscopy. Adipokines and markers of inflammation and ROS were assayed in PVAT.</p><p><strong>Results: </strong>PVAT surrounding the small arteries in control women significantly (P < .05) enhanced acetylcholine-induced endothelium-dependent relaxation and NO, and reduced contractions to thromboxane and endothelin-1. However, these effects of PVAT were reduced significantly (P < .05) in WWH whose PVAT released less adiponectin but more markers of ROS and inflammation. Moderation of contractions by PVAT were correlated positively with adipose adiponectin.</p><p><strong>Conclusions: </strong>PVAT from WWH has oxidative stress, inflammation, and reduced release of adiponectin, which may contribute to enhanced contractions and therefore could promote small-artery dysfunction.</p>","PeriodicalId":50179,"journal":{"name":"Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11272057/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of Influenza Vaccination During Pregnancy Against Laboratory-Confirmed Seasonal Influenza Among Infants Under 6 Months of Age in Ontario, Canada. 加拿大安大略省 6 个月以下婴儿在怀孕期间接种流感疫苗预防实验室确诊的季节性流感的效果。
IF 5 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-07-25 DOI: 10.1093/infdis/jiad539
Deshayne B Fell, Margaret Russell, Stephen G Fung, Sarah Swayze, Hannah Chung, Sarah A Buchan, Weston Roda, Christa Smolarchuk, Kumanan Wilson, Natasha S Crowcroft, Kevin L Schwartz, Jonathan B Gubbay, Allison J McGeer, Marek Smieja, David C Richardson, Kevin Katz, George Zahariadis, Aaron Campigotto, Samira Mubareka, J Dayre McNally, Timothy Karnauchow, Nathan Zelyas, Lawrence W Svenson, Jeffrey C Kwong

Background: Randomized trials conducted in low- and middle-income settings demonstrated efficacy of influenza vaccination during pregnancy against influenza infection among infants <6 months of age. However, vaccine effectiveness (VE) estimates from settings with different population characteristics and influenza seasonality remain limited.

Methods: We conducted a test-negative study in Ontario, Canada. All influenza virus tests among infants <6 months from 2010 to 2019 were identified and linked with health databases to ascertain information on maternal-infant dyads. VE was estimated from the odds ratio for influenza vaccination during pregnancy among cases versus controls, computed using logistic regression with adjustment for potential confounders.

Results: Among 23 806 infants tested for influenza, 1783 (7.5%) were positive and 1708 (7.2%) were born to mothers vaccinated against influenza during pregnancy. VE against laboratory-confirmed infant influenza infection was 64% (95% confidence interval [CI], 50%-74%). VE was similar by trimester of vaccination (first/second, 66% [95% CI, 40%-80%]; third, 63% [95% CI, 46%-74%]), infant age at testing (0 to <2 months, 63% [95% CI, 46%-75%]; 2 to <6 months, 64% [95% CI, 36%-79%]), and gestational age at birth (≥37 weeks, 64% [95% CI, 50%-75%]; < 37 weeks, 61% [95% CI, 4%-86%]). VE against influenza hospitalization was 67% (95% CI, 50%-78%).

Conclusions: Influenza vaccination during pregnancy offers effective protection to infants <6 months, for whom vaccines are not currently available.

背景:在中低收入国家进行的随机试验表明,在怀孕期间接种流感疫苗可有效预防婴儿感染流感:我们在加拿大安大略省进行了一项检测阴性的研究。婴儿的所有流感病毒检测结果:在接受流感检测的 23 806 名婴儿中,1783 名(7.5%)呈阳性,1708 名(7.2%)的母亲在怀孕期间接种过流感疫苗。经实验室确诊的婴儿流感感染率为 64%(95% 置信区间 [CI],50%-74%)。不同接种孕期(第一/第二孕期,66% [95% CI,40%-80%];第三孕期,63% [95% CI,46%-74%])和婴儿检测年龄(0 到结论)的 VE 相似:孕期接种流感疫苗可为婴儿提供有效保护
{"title":"Effectiveness of Influenza Vaccination During Pregnancy Against Laboratory-Confirmed Seasonal Influenza Among Infants Under 6 Months of Age in Ontario, Canada.","authors":"Deshayne B Fell, Margaret Russell, Stephen G Fung, Sarah Swayze, Hannah Chung, Sarah A Buchan, Weston Roda, Christa Smolarchuk, Kumanan Wilson, Natasha S Crowcroft, Kevin L Schwartz, Jonathan B Gubbay, Allison J McGeer, Marek Smieja, David C Richardson, Kevin Katz, George Zahariadis, Aaron Campigotto, Samira Mubareka, J Dayre McNally, Timothy Karnauchow, Nathan Zelyas, Lawrence W Svenson, Jeffrey C Kwong","doi":"10.1093/infdis/jiad539","DOIUrl":"10.1093/infdis/jiad539","url":null,"abstract":"<p><strong>Background: </strong>Randomized trials conducted in low- and middle-income settings demonstrated efficacy of influenza vaccination during pregnancy against influenza infection among infants <6 months of age. However, vaccine effectiveness (VE) estimates from settings with different population characteristics and influenza seasonality remain limited.</p><p><strong>Methods: </strong>We conducted a test-negative study in Ontario, Canada. All influenza virus tests among infants <6 months from 2010 to 2019 were identified and linked with health databases to ascertain information on maternal-infant dyads. VE was estimated from the odds ratio for influenza vaccination during pregnancy among cases versus controls, computed using logistic regression with adjustment for potential confounders.</p><p><strong>Results: </strong>Among 23 806 infants tested for influenza, 1783 (7.5%) were positive and 1708 (7.2%) were born to mothers vaccinated against influenza during pregnancy. VE against laboratory-confirmed infant influenza infection was 64% (95% confidence interval [CI], 50%-74%). VE was similar by trimester of vaccination (first/second, 66% [95% CI, 40%-80%]; third, 63% [95% CI, 46%-74%]), infant age at testing (0 to <2 months, 63% [95% CI, 46%-75%]; 2 to <6 months, 64% [95% CI, 36%-79%]), and gestational age at birth (≥37 weeks, 64% [95% CI, 50%-75%]; < 37 weeks, 61% [95% CI, 4%-86%]). VE against influenza hospitalization was 67% (95% CI, 50%-78%).</p><p><strong>Conclusions: </strong>Influenza vaccination during pregnancy offers effective protection to infants <6 months, for whom vaccines are not currently available.</p>","PeriodicalId":50179,"journal":{"name":"Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11272077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clonal Expansion of a Streptococcus pneumoniae Serotype 3 Capsule Variant Sequence Type 700 With Enhanced Vaccine Escape Potential After 13-Valent Pneumococcal Conjugate Vaccine Introduction. 肺炎链球菌血清型 3 胶囊变异序列 700 型的克隆扩增在引入 13 价肺炎球菌结合疫苗后具有增强的疫苗逃逸潜力。
IF 5 2区 医学 Q2 IMMUNOLOGY Pub Date : 2024-07-25 DOI: 10.1093/infdis/jiae040
Akuzike Kalizang'oma, Todd D Swarthout, Thandie S Mwalukomo, Arox Kamng'ona, Comfort Brown, Jacquline Msefula, Hayley Demetriou, Jia Mun Chan, Lucy Roalfe, Uri Obolski, Jose Lourenço, David Goldblatt, Chrispin Chaguza, Neil French, Robert S Heyderman

Background: Streptococcus pneumoniae serotype 3 remains a problem globally. Malawi introduced 13-valent pneumococcal conjugate vaccine (PCV13) in 2011, but there has been no direct protection against serotype 3 carriage. We explored whether vaccine escape by serotype 3 is due to clonal expansion of a lineage with a competitive advantage.

Methods: The distribution of serotype 3 Global Pneumococcal Sequence Clusters (GPSCs) and sequence types (STs) globally was assessed using sequences from the Global Pneumococcal Sequencing Project. Whole-genome sequences of 135 serotype 3 carriage isolates from Blantyre, Malawi (2015-2019) were analyzed. Comparative analysis of the capsule locus, entire genomes, antimicrobial resistance, and phylogenetic reconstructions were undertaken. Opsonophagocytosis was evaluated using serum samples from vaccinated adults and children.

Results: Serotype 3 GPSC10-ST700 isolates were most prominent in Malawi. Compared with the prototypical serotype 3 capsular polysaccharide locus sequence, 6 genes are absent, with retention of capsule polysaccharide biosynthesis. This lineage is characterized by increased antimicrobial resistance and lower susceptibility to opsonophagocytic killing.

Conclusions: A serotype 3 variant in Malawi has genotypic and phenotypic characteristics that could enhance vaccine escape and clonal expansion after post-PCV13 introduction. Genomic surveillance among high-burden populations is essential to improve the effectiveness of next-generation pneumococcal vaccines.

背景:肺炎链球菌血清 3 型仍然是全球面临的一个问题。马拉维于 2011 年引入了 13 价肺炎球菌结合疫苗 (PCV13),但仍无法直接预防血清 3 型携带。我们探讨了血清 3 型逃避疫苗接种的原因是否在于具有竞争优势的血清系的克隆扩增:方法:我们利用全球肺炎球菌测序项目(Global Pneumococcal Sequencing Project)的序列评估了血清 3 型全球肺炎球菌序列群(GPSCs)和序列类型(STs)在全球的分布情况。分析了来自马拉维布兰太尔(2015-2019 年)的 135 个血清 3 型携带分离株的全基因组序列。对胶囊位点、全基因组、抗菌药耐药性和系统发育重建进行了比较分析。使用接种过疫苗的成人和儿童的血清样本评估了嗜酸性粒细胞的吞噬能力:结果:血清型 3 GPSC10-ST700 分离物在马拉维最为常见。与原型血清型 3 胶囊多糖基因座序列相比,其中 6 个基因缺失,但保留了胶囊多糖的生物合成。这一血统的特点是抗菌性增强,对嗜蛋白细胞杀伤的敏感性降低:结论:马拉维的血清 3 型变种具有基因型和表型特征,在引入 PCV13 后可增强疫苗逃逸和克隆扩增。对高负担人群进行基因组监测对于提高下一代肺炎球菌疫苗的效果至关重要。
{"title":"Clonal Expansion of a Streptococcus pneumoniae Serotype 3 Capsule Variant Sequence Type 700 With Enhanced Vaccine Escape Potential After 13-Valent Pneumococcal Conjugate Vaccine Introduction.","authors":"Akuzike Kalizang'oma, Todd D Swarthout, Thandie S Mwalukomo, Arox Kamng'ona, Comfort Brown, Jacquline Msefula, Hayley Demetriou, Jia Mun Chan, Lucy Roalfe, Uri Obolski, Jose Lourenço, David Goldblatt, Chrispin Chaguza, Neil French, Robert S Heyderman","doi":"10.1093/infdis/jiae040","DOIUrl":"10.1093/infdis/jiae040","url":null,"abstract":"<p><strong>Background: </strong>Streptococcus pneumoniae serotype 3 remains a problem globally. Malawi introduced 13-valent pneumococcal conjugate vaccine (PCV13) in 2011, but there has been no direct protection against serotype 3 carriage. We explored whether vaccine escape by serotype 3 is due to clonal expansion of a lineage with a competitive advantage.</p><p><strong>Methods: </strong>The distribution of serotype 3 Global Pneumococcal Sequence Clusters (GPSCs) and sequence types (STs) globally was assessed using sequences from the Global Pneumococcal Sequencing Project. Whole-genome sequences of 135 serotype 3 carriage isolates from Blantyre, Malawi (2015-2019) were analyzed. Comparative analysis of the capsule locus, entire genomes, antimicrobial resistance, and phylogenetic reconstructions were undertaken. Opsonophagocytosis was evaluated using serum samples from vaccinated adults and children.</p><p><strong>Results: </strong>Serotype 3 GPSC10-ST700 isolates were most prominent in Malawi. Compared with the prototypical serotype 3 capsular polysaccharide locus sequence, 6 genes are absent, with retention of capsule polysaccharide biosynthesis. This lineage is characterized by increased antimicrobial resistance and lower susceptibility to opsonophagocytic killing.</p><p><strong>Conclusions: </strong>A serotype 3 variant in Malawi has genotypic and phenotypic characteristics that could enhance vaccine escape and clonal expansion after post-PCV13 introduction. Genomic surveillance among high-burden populations is essential to improve the effectiveness of next-generation pneumococcal vaccines.</p>","PeriodicalId":50179,"journal":{"name":"Journal of Infectious Diseases","volume":null,"pages":null},"PeriodicalIF":5.0,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11272040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Infectious Diseases
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1